Quince Therapeutics' (QNCX) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• The stock of Quince Therapeutics (QNCX) has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating continued negative sentiment from analysts.
• Quince Therapeutics reported a quarterly EPS of ($0.34), missing analysts' expectations, contributing to the overall bearish stance on the company's performance.
• The average price target for Quince Therapeutics is $8.14, with a consensus rating of "Buy" despite mixed signals from other analysts, including a $4.00 price objective from D. Boral Capital.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently commented on the company. JMP Securities lowered their price target on Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a research report on Tuesday, August 12th. Citigroup assumed coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They set an "outperform" rating for the company. Zacks Research raised Quince Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. D. Boral Capital reissued a "buy" rating and issued a $4.00 price objective on shares of Quince Therapeutics in a report on Friday, September 26th. Finally, Citizens Jmp assumed coverage on Quince Therapeutics in a report on Tuesday, August 5th. They issued a "strong-buy" rating and a $9.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $8.14.

Quince Therapeutics Stock Performance

Shares of QNCX opened at $1.92 on Wednesday. The stock has a 50-day moving average of $1.64 and a two-hundred day moving average of $1.41. Quince Therapeutics has a one year low of $0.69 and a one year high of $2.45. The company has a debt-to-equity ratio of 1.45, a quick ratio of 5.00 and a current ratio of 5.00. The stock has a market cap of $103.13 million, a P/E ratio of -1.76 and a beta of 1.07.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). As a group, research analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC increased its stake in shares of Quince Therapeutics by 48.4% in the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock valued at $58,000 after purchasing an additional 14,128 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company's stock valued at $212,000 after purchasing an additional 22,200 shares in the last quarter. XTX Topco Ltd purchased a new stake in Quince Therapeutics during the 2nd quarter worth approximately $37,000. Two Sigma Investments LP purchased a new stake in Quince Therapeutics during the 4th quarter worth approximately $57,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in Quince Therapeutics during the 2nd quarter worth approximately $280,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.